Retatrutide is an investigational "triple-G" weekly injectable medication (targeting GLP-1, GIP, and glucagon receptors). Clinical trials show it delivers exceptional weight loss of up to 24–28% of body weight, alongside massive reductions in liver and visceral fat, and improved blood sugar and blood pressure control. It is still in Phase 3 trials and not yet approved for public use. 

Major Physical and Metabolic Benefits

• Substantial weight loss: Trials show average weight reductions near 24% at 48 weeks and up to 28.7% at 68 weeks on higher doses, outperforming single or dual-agonist alternatives. 

• Increased energy expenditure: Unlike drugs relying solely on appetite suppression, adding the glucagon receptor pathway helps the body burn more calories and stored fat. 

• Dramatic fat reduction: Early data reports deep visceral abdominal fat dropping by up to 48% and liver fat decreasing by 81–86% in participants with high baseline levels. 

• Glycaemic control: Helps stabilize blood sugar, improves insulin sensitivity, and aids a vast majority of prediabetic trial participants in returning to normal blood sugar ranges.

• Cardiovascular markers: Contributes to reductions in systolic blood pressure, triglycerides, and bad cholesterol.